Form 13-F position report

GILEAD SCIENCES INC

Reported by Principal Street Partners LLC

GILD CUSIP 375558103 Manager CIK 0001759271

Reported 57,638 shares, down 595 (1.0%) from the prior quarter.

Reported value 16.8%; share count -1.0% vs. the prior quarter.

Reduced
% of reported 13F value 1.17% This manager · Q3 2026
Shares 57,638 Quarter-end amount reported
Reported value $8,590,989 Fair value at quarter end
Consecutive quarters held 28 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 432000
2022-03-31 290000
2022-06-30 302000
2022-09-30 324000
2022-12-31 6518675
2023-03-31 5336196
2023-06-30 4840990
2023-09-30 4637407
2023-12-31 4962734
2024-03-31 6271691
2024-06-30 6718448
2024-09-30 6356206
2024-12-31 7075589
2025-03-31 8606903
2025-06-30 9185601
2025-09-30 7337883
2025-12-31 7964624
2026-03-31 8218827
2026-06-30 7357191
2026-09-30 8590989

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for GILEAD SCIENCES INC held by Principal Street Partners LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 57,638 -595 (-1.0%) 1.17% $8,590,989 2026-11-16
Q2 2026 Reduced 58,233 -738 (-1.3%) 1.08% $7,357,191 2026-08-14
Q1 2026 Reduced 58,971 -5,919 (-9.1%) 1.34% $8,218,827 2026-05-15
Q4 2025 Reduced 64,890 -1,217 (-1.8%) 1.34% $7,964,624 2026-02-17
Q3 2025 Reduced 66,107 -16,743 (-20.2%) 1.17% $7,337,883 2025-11-14
Q2 2025 Added 82,850 +6,037 (7.9%) 0.9% $9,185,601 2025-08-14
Q1 2025 Added 76,813 +212 (0.3%) 1.6% $8,606,903 2025-05-15
Q4 2024 Added 76,601 +609 (0.8%) 1.39% $7,075,589 2025-02-18
Q3 2024 Reduced 75,992 -21,930 (-22.4%) 1.04% $6,356,206 2024-11-13
Q2 2024 Added 97,922 +10,003 (11.4%) 1.2% $6,718,448 2024-08-14
Q1 2024 Added 87,919 +26,658 (43.5%) 1.19% $6,271,691 2024-05-15
Q4 2023 Reduced 61,261 -621 (-1.0%) 1.2% $4,962,734 2024-02-07
Q3 2023 Reduced 61,882 -931 (-1.5%) 0.92% $4,637,407 2023-11-01
Q2 2023 Reduced 62,813 -1,502 (-2.3%) 1.15% $4,840,990 2023-08-15
Q1 2023 Reduced 64,315 -11,616 (-15.3%) 1.35% $5,336,196 2023-05-11
Q4 2022 Added 75,931 +70,689 (1348.5%) 1.64% $6,518,675 2023-02-15
Q3 2022 Added 5,242 +355 (7.3%) 0.09% $324,000 2022-11-14
Q2 2022 Added 4,887 +17 (0.3%) 0.08% $302,000 2022-08-15
Q1 2022 Reduced 4,870 -1,091 (-18.3%) 0.07% $290,000 2022-05-05
Q4 2021 Added 5,961 +267 (4.7%) 0.1% $432,000 2022-02-07
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

2482 managers reported GILEAD SCIENCES INC for Q3 2026.

Managers reporting GILEAD SCIENCES INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 125,246,865 +3,402,757 0.27% $18,668,045,217 9 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 81,175,627 +83,893 0.25% $12,099,227,204 3 qtrs
STATE STREET CORPORATION Reduced 60,954,967 -261,585 0.26% $9,085,337,831 54 qtrs
FMR LLC Reduced 58,265,696 -8,605,120 0.37% $8,684,501,953 54 qtrs
Invesco Ltd Reduced 38,662,436 -1,156,715 0.45% $5,762,636,028 54 qtrs
Capital World Investors Reduced 35,929,833 -5,059,142 0.65% $5,355,872,692 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 35,685,818 +369,650 0.24% $5,318,971,173 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 30,190,640 +124,998 0.23% $4,485,711,723 54 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 27,664,121 -2,332,573 0.41% $4,123,338,000 54 qtrs
Capital Research Global Investors Added 23,980,766 +4,587,470 0.51% $3,574,341,919 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
Common stock

Voting authority reported

Sole
57,638
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.